Log in to save to my catalogue

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an...

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2447819671

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

About this item

Full title

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Publisher

England: Elsevier Ltd

Journal title

The Lancet (British edition), 2017-12, Vol.390 (10114), p.2790-2802

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

The intensive polychemotherapy regimen eBEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses) is very active in patients with advanced-stage Hodgkin's lymphoma, albeit at the expense of severe toxicities. Individual patients might be cured with less burdensome therapy. We investi...

Alternative Titles

Full title

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2447819671

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2447819671

Other Identifiers

ISSN

0140-6736

E-ISSN

1474-547X

DOI

10.1016/S0140-6736(17)32134-7

How to access this item